Ignite Creation Date:
2024-05-05 @ 9:27 PM
Last Modification Date:
2024-10-26 @ 10:04 AM
Study NCT ID:
NCT00884949
Status:
COMPLETED
Last Update Posted:
2014-06-30
First Post:
2009-04-10
Brief Title:
A Study to Evaluate the Safety Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA
Sponsor:
BioMarin Pharmaceutical
Organization:
BioMarin Pharmaceutical
Study Overview
Official Title:
A Phase 12 Multicenter Open-label Dose-Escalation Study to Evaluate the Safety Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA Morquio Syndrome
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This multicenter open-label study is designed to assess safety dose-response using pharmacokinetic PK and pharmacodynamic PD measures and clinical efficacy of BMN 110 in subjects between 5 and 18 years of age diagnosed with Mucopolysaccharidosis IVA MPS IVA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None